Kombinované užití dendritických buněk a T buněk pro buněčnou imunoterapii nádorových onemocnění
| Název práce v češtině: | Kombinované užití dendritických buněk a T buněk pro buněčnou imunoterapii nádorových onemocnění |
|---|---|
| Název v anglickém jazyce: | A combined use of dendritic cells and T cells for cellular immunotherapy of cancer |
| Klíčová slova: | dendritické buňky, T buňky, nádorová onemocnění |
| Klíčová slova anglicky: | dendritic cells, T cells, cancer |
| Akademický rok vypsání: | 2021/2022 |
| Typ práce: | disertační práce |
| Jazyk práce: | čeština |
| Ústav: | Katedra buněčné biologie (31-151) |
| Vedoucí / školitel: | doc. RNDr. Daniel Smrž, Ph.D. |
| Řešitel: |
| Předběžná náplň práce |
| Kombinované užití dendritických buněk a T buněk pro buněčnou imunoterapii nádorových onemocnění |
| Předběžná náplň práce v anglickém jazyce |
| Cancer is one of the leading causes of death in developed countries. Traditional cancer treatments – surgery, chemotherapy, or radiation therapy – have shown considerable efficacy at the early stages of the disease. At very late stages of the disease, these treatments usually fail or have minimal efficacy. New treatment modalities that would allow an effective therapy even at very late stages of cancer are needed. Adoptive cellular immunotherapy (ACI) is a modern treatment modality for cancer treatment. Ex vivo-produced T cells are used for passive ACI of late-staged cancers. Ex vivo-produced dendritic cells (DCs) for active ACI of early-staged cancers. T cells are efficient in cancer cell elimination and DCs in eliciting long-lasting anti-cancer immune immunity. The combined use of both cell types for ACI could synergize the treatment efficacy of cancer. The Ph.D. student will investigate the efficacy of combined use of ex vivo-produced monocyte-derived DCs and T cells in the elimination of cancer cells. This efficacy will be primarily evaluated in vitro. The first part of the project will consist of ex vivo-production of both cell types from peripheral blood of healthy donors. The second part will consist of functional analyses of these cells, including their phenotype, cytotoxic activity, and maturation. As a model will be used prostate cancer cell lines LNCaP, PC-3, and DU-145. The methods used will be cell isolation and culturing, flow cytometry, immunoblotting, and microscopy. CV and motivation letter to: daniel.smrz@lfmotol.cuni.cz |